<DOC>
	<DOCNO>NCT02517372</DOCNO>
	<brief_summary>This study single-centre , open-label , dose escalation , safety , tolerability pharmacokinetics ( PK ) study healthy male female subject . The study include screen day 5-day dosing period . Subjects enrol sequential cohort cohort include 8 subject . 24 subject total include study . The duration clinical part study approximately 2 month .</brief_summary>
	<brief_title>Study Healthy Volunteers Document Safety Tolerability Increasing Doses Pemirolast</brief_title>
	<detailed_description>Subjects meet eligibility criterion screen remain clinic evening precede first day dose ( Day - 1 ) investigational medical product ( IMP ) check clinic 24 hour first dose administration IMP ( morning Day 2 ) . Dose administration IMP even Day 2 morning even dose Days 3 4 perform home . The subject check-in morning Day 5 receive last dose administration IMP stay clinic 12 hour post dose . All subject within cohort receive dose IMP . There 3 cohort ( dose-levels ) 8 subject cohort correspond 24 subject total . Within cohort subject dose group 4 . There 24 hour dose group 15 minute dose subject group . There interval approximately least 1-week interval cohort allow time compilation evaluation data Internal Safety Review Committee meeting . Subsequent cohort administer increase dos either maximum tolerate dose ( MTD ) study maximum dose ( SMD ) reach .</detailed_description>
	<mesh_term>Pemirolast</mesh_term>
	<criteria>Written inform consent , healthy subject age 1965 year Significant concurrent disease medical condition deem interfere safety pharmacokinetics CRD007 conduct trial</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>